Altogether, treatment with PIVOT led to a robust anti-tumor response, as evidenced by enhanced functional CD8+ TIL activity, increased numbers of CD11C+MHCII+ DCs at the tumor site, and improved tumor regression in a murine B16-F10 model. The gene discussed is ITGAX; the disease is neoplasm.